A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults
about
A review of malaria vaccine clinical projects based on the WHO rainbow tableVaccines for preventing malaria (pre-erythrocytic)Identification of Novel Pre-Erythrocytic Malaria Antigen Candidates for Combination Vaccines with Circumsporozoite ProteinInterrogating the Plasmodium Sporozoite Surface: Identification of Surface-Exposed Proteins and Demonstration of Glycosylation on CSP and TRAP by Mass Spectrometry-Based ProteomicsA phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in KenyaEnrolling adolescents in HIV vaccine trials: reflections on legal complexities from South Africa.Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategiesImmunological mechanisms underlying protection mediated by RTS,S: a review of the available data.Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model.Malaria immunity in man and mosquito: insights into unsolved mysteries of a deadly infectious disease.Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens.New gorilla adenovirus vaccine vectors induce potent immune responses and protection in a mouse malaria model.A novel MVA vectored Chikungunya virus vaccine elicits protective immunity in mice.Advances and challenges in malaria vaccine development.Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+T cells targeting AMA1 class I epitopesImproving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein.Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populationsPlasmodium immunomics.Immunological responses against Plasmodium falciparum Apical Membrane Antigen 1 vaccines vary depending on the population immunizedA phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.Selection and quantification of infection endpoints for trials of vaccines against intestinal helminthsA DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.Chronic Infection by Mucoid Pseudomonas aeruginosa Associated with Dysregulation in T-Cell Immunity to Outer Membrane Porin FStrategies for developing multi-epitope, subunit-based, chemically synthesized anti-malarial vaccines.A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria.Building better T-cell-inducing malaria vaccines.Malaria vaccines in development.Advances in vaccine development against the pre-erythrocytic stage of Plasmodium falciparum malaria.Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults.Progress with viral vectored malaria vaccines: A multi-stage approach involving "unnatural immunity".Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques.Pre-erythrocytic malaria vaccines: towards greater efficacy.Tuberculosis vaccines: current status and future prospects.Relevance of long-lived CD8(+) T effector memory cells for protective immunity elicited by heterologous prime-boost vaccination.Malaria treatment with atovaquone-proguanil in malaria-immune adults: implications for malaria intervention trials and for pre-exposure prophylaxis of malaria.Pre-erythrocytic malaria vaccines: identifying the targets.Identification of non-CSP antigens bearing CD8 epitopes in mice immunized with irradiated sporozoites.Vaccines against malaria - an update.Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.
P2860
Q21034112-7F011834-0E8F-414F-B95E-37994A3FC726Q24244317-6A8D7AC1-676A-4DB3-AC24-97AB133426A0Q27973488-A39E5FC6-844C-4DC6-853A-A4279C9C4C97Q27973871-EC9A1136-FBD8-47D0-A271-DC12AC13D7D3Q28469062-265972E0-84A1-4ADC-8BFD-8722C3C944F7Q33284467-1E572B88-F303-43C9-BC45-78B0D84E2627Q33440600-DD159662-EFC5-4374-AB98-117EAF8705F2Q33521372-CCA8C978-4053-43A7-916C-569F7EAA2AE5Q33587443-D7A6286B-B4A9-4B71-BB24-81673499BFF2Q33821137-6E2CCFA0-B23B-4C56-8056-20CA90BBE82BQ33843258-D1FEF917-029A-436B-A5AF-D3DA41D50D66Q33868760-82A9ED58-F156-4A11-B147-5A75B382CC25Q33945612-19DEC335-1572-4A7E-BFEF-9166D075F5F1Q34145333-0310E28D-D38E-4EE7-8891-38A4C77B795EQ34165879-96B7E484-591B-4F67-B9F5-1B5E72DBAF4DQ34182371-27296B93-734A-4D92-AC89-E44EB730CACBQ34301461-55B351B1-A68A-4D7E-BECB-84DEA575CE46Q34419934-B65FBC11-B80A-416E-A6B5-F280B410B1BFQ34612788-C368A576-902B-47E8-A95B-1D079BFD52B2Q34734075-3592D70A-4055-4A5C-845B-FFF3F246785BQ34978256-7CF1130D-E032-4412-B67F-7A2CD5EE009DQ35073970-7BBFEBAA-CCBD-433E-B328-07C8DA7D842CQ35741984-D7946FCC-2689-46BC-8436-C3FFDBE84843Q35766685-2B4D8FE4-4D80-499E-AC79-448AAA2B37EDQ35862464-9BF64556-6104-4391-83B8-BBDD6CAAD9ECQ35927866-8B3D3D6E-7692-49AB-9804-8B41021A7BE5Q36122648-30A70847-4E3B-481A-BDC8-F91FC6A1A443Q36219634-11711E88-8567-4F05-9DA4-AF6C63220D1EQ36383811-FA777BF5-9361-4F38-A726-099F7194B886Q36393102-3BDBA07A-1C41-4D36-A196-BE5AB9A5350AQ36394177-CA191A9F-AE8E-471F-A956-BF5151497496Q36397581-25BD298E-F76D-4AEE-98FB-2A4F9FC1A3F0Q36403400-4DCE4978-696A-4145-876C-201ABA24EF96Q36458393-3E1631A4-D73E-4325-AFBC-AA7CF4D6779EQ36474557-1E49AE19-05FD-407E-9177-453A59C16D6DQ36538784-D3484F3D-931A-48B3-AD09-CA15DB859389Q36644236-CC7DC1BD-28BE-465F-A5E6-F1EE3B2EEF56Q36702125-99C7C077-0741-4CE4-BE9E-BB43BC08BE48Q36933780-C0F469B8-2BA7-4B2D-8045-72129915F416Q37073334-6DE23891-9553-4626-A3D7-FCC8791EDE93
P2860
A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults
description
2004 nî lūn-bûn
@nan
2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
A randomised, double-blind, co ...... ia infection in Gambian adults
@ast
A randomised, double-blind, co ...... ia infection in Gambian adults
@en
A randomised, double-blind, co ...... ia infection in Gambian adults
@nl
type
label
A randomised, double-blind, co ...... ia infection in Gambian adults
@ast
A randomised, double-blind, co ...... ia infection in Gambian adults
@en
A randomised, double-blind, co ...... ia infection in Gambian adults
@nl
prefLabel
A randomised, double-blind, co ...... ia infection in Gambian adults
@ast
A randomised, double-blind, co ...... ia infection in Gambian adults
@en
A randomised, double-blind, co ...... ia infection in Gambian adults
@nl
P2093
P2860
P50
P3181
P1433
P1476
A randomised, double-blind, co ...... ia infection in Gambian adults
@en
P2093
Adrian S V Hill
Brian M Greenwood
Pauline Kaye
P2860
P3181
P356
10.1371/JOURNAL.PMED.0010033
P407
P50
P577
2004-11-01T00:00:00Z